KPMG: US M&A Activity to Spur Pharma Growth

According to a survey by audit, tax and advisory firm KPMG, US pharmaceutical firms will be on the acquisition hunt over the next two years.

A survey, which polled 100 senior executives in the US pharmaceutical industry, performed by audit, tax and advisory firm KPMG, says US pharmaceutical firms will be on the acquisition hunt over the next two years.

In the KPMG Pharmaceutical Industry Pulse survey, 83% said it is likely that their company would be involved in an acquisition or merger as a buyer or seller in the next two years. Some 41% said the largest area of spending in the next year would be for acquisitions, followed by new products and services (38%), and research and development (38%).

A strategic acquisition was cited as the highest priority investment area by 41% of executives, followed by expansion into new markets (22%).

&nbs